Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas

Figures & data

TABLE 1 T-cell lymphoma immunophenotypes

Lymphoma	Immunophenotype
T-lymphoblastic lymphoma	Cytoplasmic CD3, CD4, CD8, CD7±
T-cell prolymphocytic leukemia	CD2, CD3, CD7, CD4± or CD8±
T-cell large granular lymphocyte leukemia	CD3, TCRãb, CD8, CD57, CD122
HTLV-1 adult T-cell leukemia/lymphoma	CD2, CD3, CD4, CD5, CD25, CD52
Extranodal NK/T-cell lymphoma (nasal)	CD2, CD3, CD56
Enteropathy-type T-cell lymphoma	CD3, CD7, CD30, CD103,
Hepatosplenic T-cell lymphoma	CD3, CD8±, TCRg, CD56
Subcutaneous panniculus-like T-cell lymphoma	CD3, CD8,
Mycosis fungoides/Sezary Syndrome	CD2, CD3, CD5, CD4, CD8-, CD7-
Primary cutaneous CD30-positive	CD30
T-lymphoproliferative disorders
Angioimmunoblastic T-cell lymphoma	CD3, CD4, CD10
Peripheral T-cell lymphoma (NOS)	CD3, CD2, CD4 or CD8, CD5, CD7±
Systemic anaplastic large cell lymphoma	CD30, CD2, CD4, CD8-, CD3±, CD5±

TABLE 2 World Health Organization (WHO) classification of T-cell and NK cell lymphoid tumors^a

Precursor T-cell neoplasms

T-cell lymphoblastic leukemia/lymphoma

Blastic NK cell lymphoma

Mature T-cell and NK cell neoplasms

T-cell prolymphocytic leukemia

T-cell large granular lymphocyte leukemia

Aggressive NK cell leukemia

Human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma

Extranodal NK/T-cell lymphoma, nasal type

Enteropathy-type T-cell lymphoma

Hepatosplenic T-cell lymphoma

Subcutaneous panniculitis-like T-cell lymphoma

Mycosis fungoides/Sezary syndrome

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders:

Primary cutaneous anaplastic large cell lymphoma

Lymphomatoid papulomatosis

Borderline lesions

Angiommunoblastic T-cell lymphoma

Peripheral T-cell lymphoma (not otherwise specified)

Systemic anaplastic large cell lymphoma

T-cell lymphoproliferation of uncertain malignant potential

Lymphomatoid papulosis

^aJaffe et al. (2001).

FIG. 1 Target antigens for receptor-directed therapy of T-cell leukemias and lymphomas.

TABLE 3 Receptor-directed therapy for T-cell leukemia and lymphoma

Target	Description	Targeting Agent	References
CD2	LFA-3 (CD58) receptor	Alefacept (Amevive) Slipizumab (MEDI-507)	Majeau et al. (1994); Branco et al. (1999)
CD3	Signaling chain (CD3ζ) of the T-cell receptor (TCR)	Muromonab-CD3 (Orthoclone, OKT3)	Kung et al. (1979)
CD4	TCR co-receptor	Anti-Leu3a cM-T412 Zanolimumab (HuMax-CD4)	Knox et al. (1991); Knox et al. (1996); Kim et al. (2007)
CD5	Scavenger receptor family member	Anti-Leu1 T101 Anti-CD5-ricin A (CD5-Plus)	Muller et al. (1983); Dillman et al. (1984); Ravel et al. (1992)
CD25	IL-2 receptor α -subunit	Murine anti-Tac Daclizumab (Zenapax) Denileukin diftitox (Ontak)	Uchiyama et al. (1981a); Queen et al. (1989); Foss et al. (1998)
CD30	TNF receptor family member	Ber-H2 Hefi-1 MDX-060 SGN-30 SGN-35	Norton and Issacson (1987); Hecht et al. (1985); Borchmann et al., (2003); Bowen et al., (1993); Hamblett et al. (2005)
CD52	GPI-anchored glycoprotein	Alemtuzumab (Campath)	Hale et al. (1983)
CD122	IL-2 and IL-15 receptor β -subunit	Murine and humanized Mik-β 1	Tsudo et al. (1989); Hakimi et al. (1993)

Jaffe E. S., Harris N. L., Stein H., Vardiman J. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, LyonFrance 2001

 Google Scholar

Majeau G. R., Meier W., Jimmo B., Kioussis D., Hochman P. S. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T-cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 1994; 152: 2753–2767

 PubMed Web of Science ®Google Scholar

Branco L., Barren P., Mao S. Y., Pfarr D., Kaplan R., Postema C., Langermann S., Koenig S., Johnson S. Selective deletion of antigen-specific, activated T-cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588–1596

 PubMedGoogle Scholar

Kung P., Goldstein G., Reinherz E. L., Schlossman S. F. Monoclonal antibodies defining distinctive human T-cell surface antigens. Science 1979; 206: 347–349

 PubMed Web of Science ®Google Scholar

Knox S. J., Levy R., Hodgkinson S., Bell R., Brown S., Wood G. S., Hoppe R., Abel E. A., Steinman L., Berger R. G., Gaiser C., Young G., Bindl J., Hanham A., Reichert T. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991; 77: 20–30

 PubMed Web of Science ®Google Scholar

Knox S., Hoppe R. T., Maloney D., Gibbs I., Fowler S., Marquez C., Cornbleet P. J., Levy R. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893–899

 PubMedGoogle Scholar

Kim J. G., Sohn S. K., Chae Y. S., Cho Y. Y., Yang D. H., Lee J. J., Kim H. J., Shin H. J., Chung J. S., Cho G. J., Lee W. S., Joo Y. D., Sohn C. H., Oh S. J. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: A Phase II study. Cancer Chemother. Pharmacol. 2007; 60: 129–134

 PubMed Web of Science ®Google Scholar

Dillman R. O., Shawler D. L., Dillman J. B., Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol. 1984; 2: 881–891

 PubMed Web of Science ®Google Scholar

Ravel S., Colombatti M., Casellas P. Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T-cells. Blood 1992; 79: 1511–1517

 PubMedGoogle Scholar

Uchiyama T., Broder S., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 1981a; 126: 1393–1397

 PubMed Web of Science ®Google Scholar

Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P., Waldmann T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 1989; 86: 10029–10033

 PubMed Web of Science ®Google Scholar

Foss F. M., Saleh M. N., Krueger J. G., Nichols J. C., Murphy J. R. Diphtheria toxin fusion proteins. Curr. Top. Microbiol. Immunol. 1998; 234: 63–81

 PubMed Web of Science ®Google Scholar

Norton A. J., Isaacson P. G. Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. Am. J. Pathol. 1987; 128: 225–240

 PubMed Web of Science ®Google Scholar

Hecht T. T., Longo D. L., Cossman J., Bolen J. B., Hsu S. M., Israel M., Fisher R. I. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J. Immunol. 1985; 134: 4231–4236

 PubMed Web of Science ®Google Scholar

Borchmann P., Treml J. F., Hansen H., Gottstein C., Schnell R., Staak O., Zhang H. F., Davis T., Keler T., Diehl V., Graziano R. F., Engert A. The human anti-CD30 antibody 5F11 shows in vitro in vivo activity against malignant lymphoma. Blood 2003; 102: 3737–3742

 PubMed Web of Science ®Google Scholar

Bowen M. A., Olsen K. J., Cheng L., Avila D., Podack E. R. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J. Immunol. 1993; 151: 5896–5906

 PubMed Web of Science ®Google Scholar

Hamblett K. J., Barton J., Cerveny C. G., Andreyka J. B., Kissler K. M., Okeley N. M., Stone I., Sutherland M. K., Sun M. M., Senter P. D., Wahl A. F., Ihle N. C. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent anti-tumor activity for the treatment of CD30+ malignancies. Blood 2005; 106: 610, (ASH Annual Meeting Abstracts)

 Google Scholar

Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A. J., Waldmann H. Removal of T-cells from bone marrow for transplantation: A monoclonal anti-lymphocyte antibody that fixes human complement. Blood 1983; 62: 873–882

 PubMed Web of Science ®Google Scholar

Tsudo M., Kitamura F., Miyasaka M. Characterization of the IL-2 receptor β chain using three distinct monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1989; 86: 1982–1986

 PubMed Web of Science ®Google Scholar

Hakimi J., Ha V. C., Lin P., Campbell E., Gately M. K., Tsudo M., Payne P. W., Waldmann T. A., Grant A. J., Tsien W. H., Schneider W. P. Humanized Mik β 1, a humanized antibody to the IL-2 receptor β -chain that acts synergistically with humanized anti-TAC. J. Immunol. 1993; 151: 1075–1085

 PubMed Web of Science ®Google Scholar